Incorporating clinical considerations into statistical analyses of markers: A quiet revolution in how we think about data

Clinical Chemistry

Volumn 62, Issue 5, 2016, Pages 671-672

  Vickers, Andrew J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AREA UNDER THE CURVE; BIOSTATISTICS; CLINICAL PRACTICE; CORRELATION COEFFICIENT; COST BENEFIT ANALYSIS; DATA ANALYSIS; EDITORIAL; HUMAN; MEDICAL DECISION MAKING; PROBABILITY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; DECISION SUPPORT SYSTEM;

BIOMARKERS; BIOSTATISTICS; DECISION SUPPORT TECHNIQUES; HUMANS;

EID: 84964913132     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.254268     Document Type: Editorial

References (4)

1. Pepe M, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem 2016;62:737-42.
2. Pauker SG, Kassirer JP. Therapeutic decision making: a cost-benefit analysis. N Engl J Med 1975;293:229-34.
3. Vickers AJ, Pepe M. Does the net reclassification improvement helpusevaluate models and markers? Ann Intern Med 2014;160:136-7.
4. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-74.